Ref ID: 17698
Author:
A. Cheng*, H.Y. Sun, B.S.K. Ko, H.F. Tien, Y.C. Chen,
S.C. Chang
Author address:
(Taipei, TW)
Full conference title:
22nd European Congress of Clinical Microbiology and Infectious Diseases
Abstract:
Objectives: To assess incidence and risk factors of breakthrough
mycosis under micafungin prophylaxis for hematopoietic stem cell
transplantation (HSCT).
Methods: A total of 50 HSCT recipients receiving micafungin as
prophylaxis in 2010-2011 were analyzed. Patients were followed for
100 days post-transplantation for the development of mycosis defined
by EORTC.
Results: Of the 50 patients, 38% received HSCT for lymphoma, 18%
for AML, 14% for ALL, and 14% for MDS; 40% received allogenetic
and 36% autologous HSCT. Breakthrough mycosis developed in 4
(8%) patients, including probable aspergillosis in 3 and definite
trichosporosis in 1, after a median of 6 days post-transplant and after
micafungin use for a median of 16 days. Of the three patients with
probable aspergillosis, persistent elevation of aspergillus antigen levels
and newly developed pulmonary nodules were the most common
presentations. The case with trichosporosis developed fever and
disseminated papular rash, and Trichosporon species was isolated
from the blood. All these four patients were successfully treated with
voriconazole. Compared with 46 patients without breakthrough
mycosis, positive cases were more like to be older (mean, 53 vs.
43 years old, p < 0.05) and had graft-versus-host-disease (50% vs.
28.3%, p > 0.05). All patients had surveillance nasal and throat fungal
cultures post-transplant, and 10 patients had positive results, including
C. albican in seven patients, C. glabrata in 1, unidentified Candida
species in 1, Trichosporon species in 1, and Mycelium sterile in 1.
Conclusion: The incidence of breakthrough mycosis during
micafungin prophylaxis for HSCT was 8%. Although micafungin had
anti-Aspergillus attribute, aspergillosis was the most common
breakthrough mycosis.
Abstract Number: NULL
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Aude Allemand1, Isabel Valsecchi1, Emilie Bequignon2, Sebastien Gallien1, Coste Andre2, Bruno Louis2, Francoise Botterel1
2024
70
n/a
-
v
Sara Gago (UK)
2024
69
n/a
-
v
Laura Seldeslachts (BE)
2024
67
n/a
-
v
Xabier Guruceaga (US)
2024
66
n/a
-
v
Nayanna Mercado Soto (US)
2024
65
n/a
-
v
Rucha Karad,Bibhuti Saha,Soumendranath Haldar
2024
64
n/a
-
v
Professor Wei Liu (CN)
Xinyu Yang1,2,3,4#, Qian Wang1,2,3,4#, Binghan Xiao5, Qiqi Wang1,2,3,4, Weiwei Deng1,2,3,4, Ruoyu Li1,2,3,4, Wei Liu1,2,3,4*2024
63
n/a